Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Is there any data on the safety or efficacy of combining osimertinib-based therapy with HER2-targeted treatment in patients with EGFR-mutant NSCLC and concurrent HER2-positive breast cancer?
Related Questions
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?
What treatment would you recommend for a patient with non-mutated Stage III lung squamous cell carcinoma with relapse following neoadjuvant chemoimmunotherapy, surgery, and during adjuvant immunotherapy?
In ALK + metastatic NSCLC patients who have widespread progression on first line lorlatinib how do you determine your next line of therapy and what is your preference?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
How would you approach post-chemoradiation consolidation in a patient with stage III lung adenocarcinoma with an EGFR exon 18 G719A mutation and highly positive PD-L1 level?
